Skip to content

Day 1 — Monday Jan 12, 2026

Source: synthesized from public coverage (see Sources). Unlike the Nextflow vault, this digest has no primary transcripts — JPM is invite-only and most content is reconstructed from trade-press reporting and company press releases.

The 44th J.P. Morgan Healthcare Conference opened in San Francisco with an unusually quiet news flow by historical standards: no megadeal M&A and no surprise blockbuster acquisitions. Day 1 was anchored by a $1B Lilly–NVIDIA AI alliance, a $5.6B AbbVie/RemeGen PD-1×VEGF licensing deal, and a ~$1.7B Novartis/SciNeuro Alzheimer's pact — alongside a heavy slate of fireside chats from BMS, Pfizer, J&J, Regeneron, Biogen, Moderna, Alnylam, argenx, BridgeBio, Sarepta, Summit, and CRISPR Therapeutics. Multiple observers (Takeda R&D chief Andy Plump; investor Brad Loncar) flagged the slow Monday cadence as a contrast with prior years.

1. NVIDIA + Eli Lilly — $1B AI Co-Innovation Lab

  • Up to $1B over 5 years, jointly funded, to build an AI Co-Innovation Lab in the SF Bay Area co-locating Lilly biology/scientific staff with NVIDIA AI engineers.
  • Built on NVIDIA BioNeMo platform and NVIDIA Vera Rubin architecture; aim is closed-loop drug discovery plus AI applications across manufacturing and commercial.
  • Kimberly Powell (NVIDIA VP, Healthcare) led the press briefing.

Why it matters: Largest pharma–AI infrastructure commitment announced at JPM26 Day 1; sets the tone for the AI/bio convergence theme.

Sources: Lilly press release; Clinical Trials Arena.

2. AbbVie + RemeGen — $5.6B PD-1×VEGF bispecific licensing

  • $650M upfront, up to $4.95B in milestones, plus tiered double-digit royalties; ex-Greater China rights to RC148, a PD-1/VEGF bispecific antibody.
  • Therapeutic area: advanced solid tumors (NSCLC, CRC focus); Phase 2 asset.
  • Strategic rationale: combination potential with AbbVie ADCs including telisotuzumab adizutecan (Temab-A).

Why it matters: Largest deal announced on Day 1; another China-origin asset crosses to Big Pharma; intensifies the PD-1×VEGF bispecific race (vs. Summit's ivonescimab).

Sources: AbbVie press release; Fierce Biotech.

3. Novartis + SciNeuro — ~$1.7B Alzheimer's antibody pact

  • $165M upfront, up to ~$1.5B in development/regulatory/sales milestones plus royalties. Worldwide license.
  • Asset: de novo amyloid-beta antibody candidates with SciNeuro's proprietary brain-shuttle delivery technology designed to improve BBB penetration.
  • Therapeutic area: Alzheimer's disease; expected close 1H 2026.

Why it matters: Differentiated delivery tech vs. approved anti-amyloid antibodies; positions Novartis in an active neuro-licensing market.

Sources: SciNeuro/PRNewswire; Fierce Biotech.

4. Bristol Myers Squibb — CEO showcases blockbuster pipeline

  • CEO Chris Boerner highlighted six multi-billion-dollar candidates: Cobenfy (Alzheimer's psychosis), milvexian (FXIa, J&J-partnered, AFib/stroke), admilparant (IPF), pumitamig (PD-L1×VEGF, BioNTech-partnered), and CELMoDs iberdomide & mezigdomide (multiple myeloma).
  • Pivotal 2026 readouts: three Adept trials (Cobenfy in Alzheimer's psychosis), milvexian, admilparant, both CELMoDs.
  • Targeting >10 new launches by 2030; BD remains a top capital-allocation priority.

Why it matters: Investor narrative for BMS hinges on pipeline diversification past LOEs.

Sources: Fierce Pharma JPM26 Day 1 tracker; Endpoints Q&A with Boerner.

5. Pfizer — obesity strategy on the back of $10B Metsera

  • CEO Albert Bourla projected the obesity market reaching $150B by 2030; compared expected demand to the original Viagra rollout.
  • Metsera acquisition (announced Sept 2025, closed Nov 2025) anchors a portfolio built around monthly injectables and oral combos, including PF-3944/MET-097i (ultra-long-acting GLP-1 in Ph2b).
  • Plans up to ~10 Phase 3 obesity trials via the Metsera platform in 2026.

Why it matters: Pfizer's re-entry into obesity after the danuglipron failure; differentiation play vs. Lilly/Novo.

Sources: Pfizer JPM 2026 fireside chat deck (PDF); BioPharma Dive.

6. Amgen — MariTide (maridebart cafraglutide) Phase 2 update

  • Monday-evening reveal of Phase 2 obesity and Phase 2 T2D data on the once-monthly GLP-1/GIPR-antagonist peptibody.
  • T2D arm: clinically meaningful HbA1c and body-weight reductions at 24 weeks on monthly dosing; favorable cardiometabolic profile.
  • Tolerability consistent with GLP-1 RA class; six global Phase 3 studies underway.

Why it matters: Reinforces Amgen's positioning as a third obesity major behind Lilly and Novo; monthly dosing as differentiator.

Source: Clinical Trials Arena.

7. BridgeBio — Attruby Q4 commercial beat

  • Preliminary Q4 2025 Attruby (acoramidis) net revenue of $146M, ahead of consensus; +35% QoQ.
  • 6,629 unique patient prescriptions from 1,632 prescribers as of Dec 31, 2025.
  • Leerink raised PT to $75; Morgan Stanley initiated Overweight with $96 PT.

Why it matters: Validates ATTR-CM commercial trajectory and BridgeBio's transition to revenue-generating biotech.

Source: BridgeBio investor release.

8. Sarepta — Elevidys re-commitment, prelim 2025 sales

  • CEO Doug Ingram doubled down on DMD gene therapy Elevidys despite 2025 safety controversies (two patient deaths, FDA back-and-forth).
  • Preliminary 2025 total sales: $1.86B; Elevidys contributed $898.7M.

Why it matters: Sets the tone for Sarepta's recovery narrative entering 2026.

Source: BioPharma Dive.

9. Biogen — high-dose Spinraza approved by European Commission

  • EC marketing authorization for high-dose nusinersen (50 mg/5 mL and 28 mg/5 mL) in 5q SMA, granted same day as Biogen's JPM presentation.
  • Backed by DEVOTE study data in treatment-naïve and previously-treated patients. Already approved in Japan; FDA action by April 3, 2026.

Why it matters: Shores up an aging franchise on the morning Biogen presented its "new Biogen" pivot; CEO Chris Viehbacher emphasized continued immunology build-out via HI-Bio.

Source: Biogen press release.

10. Moderna — 2025 sales beat, 2026 growth guide

  • Preliminary unaudited 2025 sales of $1.9B (~$100M above midpoint of guidance).
  • 2026 outlook: up to ~10% sales growth on a "large seasonal vaccine franchise" plus pipeline progression (CEO Stéphane Bancel).

Why it matters: Steadies the Moderna investor narrative post-COVID-revenue cliff.

Source: STAT JPM 2026 Day 1 recap.

Smaller items / notable mentions

  • J&J fireside chat at 11:15 am ET; pipeline/financial guidance, no headline deal.
  • Regeneron (Schleifer + Yancopoulos) outlined five late-stage near-term readouts across oncology, obesity, complement, anticoagulation, and immunology.
  • Alnylam unveiled "Alnylam 2030" — three pillars: scale with discipline, global TTR leadership, sustainable innovation; cited 300K global ATTR-CM patients with ~80% undiagnosed.
  • CRISPR Therapeutics highlighted CASGEVY global rollout and in vivo cardiovascular/autoimmune programs.
  • Summit Therapeutics presented Monday hours after AbbVie/RemeGen news re-priced the PD-1×VEGF competitive set.
  • Waystar (Matt Hawkins) projected RCM TAM expanding from $20–25B to $55B with AI; touted Iodine acquisition data leverage; processed 7.5B claims in 2025.
  • Advocate Health CEO Eugene Woods cited $1.5B in annual operating savings since the 3-year-old merger.
  • Takeda R&D head Andy Plump publicly noted the absence of major deal announcements Monday morning, hoped for M&A later in the week.
  • Investor Brad Loncar: "This [has] been the slowest JPM for news in a long time."
  • Pre-JPM follow-on financings hit a record $2.6B for the month so far (STAT).

Themes emerging by end of Day 1

  • AI/bio convergence as headline theme — Lilly–NVIDIA $1B lab framed Day 1; AI also dominated health-tech presentations (Waystar agentic AI).
  • Licensing displacing M&A — Day 1 produced ~$7.3B in announced licensing value (AbbVie/RemeGen, Novartis/SciNeuro) but zero megadeals; multiple commentators flagged a "slow Monday."
  • Obesity remains the gravitational center — Pfizer (Metsera), Amgen (MariTide), and the broader Lilly/Novo backdrop drove a disproportionate share of Day 1 narrative.
  • China-origin assets continue moving west — RC148 (RemeGen) and the SciNeuro brain-shuttle platform both originated in China.

Sources

See Themes & takeaways for cross-day synthesis.